A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 in Participants with Advanced Solid Tumors
Latest Information Update: 01 Apr 2025
At a glance
- Drugs HS 20110 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hansoh BioMedical R&D Company
- 01 Apr 2025 New trial record